Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting

Iván Plaza-Menacho, Luca Mologni, Elisa Sala, Carlo Gambacorti-Passerini, Anthony I. Magee, Thera P. Links, Robert M W Hofstra, David Barford, Clare M. Isacke

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Germ line missense mutations in the RET (rearranged during transfection) oncogene are the cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only treatment available for MEN2 patients. In this study, the ability of Sorafenib (BAY 43-9006) to act as a RET inhibitor was investigated. Sorafenib inhibited the activity of purified recombinant kinase domain of wild type RET and RETV804M with IC50 values of 5.9 and 7.9 nM, respectively. Interestingly, these values were 6-7-fold lower than the IC50 for the inhibition of B-RAFV600E. In cell-based assays, Sorafenib inhibited the kinase activity and signaling of wild type and oncogenic RET in MEN2 tumor and established cell lines at a concentration between 15 and 150 nM. In contrast, inhibition of oncogenic B-RAF- or epidermal growth factor-induced ERK1/2 phosphorylation required micromolar concentrations of Sorafenib demonstrating the high specificity of this drug in targeting RET. Moreover, prolonged exposure to Sorafenib resulted in inhibition of cell proliferation and RET protein degradation. Using lysosomal and proteasomal inhibitors, we demonstrate that Sorafenib induces RET lysosomal degradation independent of proteasomal targeting. Furthermore, we provide a structural model of the Sorafenib·RET complex in which Sorafenib binds to and induces the DFGout conformation of the RET kinase domain. These results strengthen the argument that Sorafenib may be effective in the treatment of MEN2 patients. In addition, because inhibition of RET is not impaired by mutation of the Val804 gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance.

Original languageEnglish
Pages (from-to)29230-29240
Number of pages11
JournalJournal of Biological Chemistry
Volume282
Issue number40
DOIs
Publication statusPublished - Oct 5 2007

Fingerprint

Protein-Tyrosine Kinases
Transfection
Multiple Endocrine Neoplasia Type 2a
Degradation
Phosphotransferases
Inhibitory Concentration 50
Tumors
sorafenib
Phosphorylation
Germ-Line Mutation
Structural Models
Cell proliferation
Corrosion inhibitors
Missense Mutation
Drug Delivery Systems
Tumor Cell Line
Oncogenes
Epidermal Growth Factor
Surgery
Proteolysis

ASJC Scopus subject areas

  • Biochemistry

Cite this

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. / Plaza-Menacho, Iván; Mologni, Luca; Sala, Elisa; Gambacorti-Passerini, Carlo; Magee, Anthony I.; Links, Thera P.; Hofstra, Robert M W; Barford, David; Isacke, Clare M.

In: Journal of Biological Chemistry, Vol. 282, No. 40, 05.10.2007, p. 29230-29240.

Research output: Contribution to journalArticle

Plaza-Menacho, I, Mologni, L, Sala, E, Gambacorti-Passerini, C, Magee, AI, Links, TP, Hofstra, RMW, Barford, D & Isacke, CM 2007, 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting', Journal of Biological Chemistry, vol. 282, no. 40, pp. 29230-29240. https://doi.org/10.1074/jbc.M703461200
Plaza-Menacho, Iván ; Mologni, Luca ; Sala, Elisa ; Gambacorti-Passerini, Carlo ; Magee, Anthony I. ; Links, Thera P. ; Hofstra, Robert M W ; Barford, David ; Isacke, Clare M. / Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. In: Journal of Biological Chemistry. 2007 ; Vol. 282, No. 40. pp. 29230-29240.
@article{eb5436d9788c4d88b045b4ac1adca33d,
title = "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting",
abstract = "Germ line missense mutations in the RET (rearranged during transfection) oncogene are the cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only treatment available for MEN2 patients. In this study, the ability of Sorafenib (BAY 43-9006) to act as a RET inhibitor was investigated. Sorafenib inhibited the activity of purified recombinant kinase domain of wild type RET and RETV804M with IC50 values of 5.9 and 7.9 nM, respectively. Interestingly, these values were 6-7-fold lower than the IC50 for the inhibition of B-RAFV600E. In cell-based assays, Sorafenib inhibited the kinase activity and signaling of wild type and oncogenic RET in MEN2 tumor and established cell lines at a concentration between 15 and 150 nM. In contrast, inhibition of oncogenic B-RAF- or epidermal growth factor-induced ERK1/2 phosphorylation required micromolar concentrations of Sorafenib demonstrating the high specificity of this drug in targeting RET. Moreover, prolonged exposure to Sorafenib resulted in inhibition of cell proliferation and RET protein degradation. Using lysosomal and proteasomal inhibitors, we demonstrate that Sorafenib induces RET lysosomal degradation independent of proteasomal targeting. Furthermore, we provide a structural model of the Sorafenib·RET complex in which Sorafenib binds to and induces the DFGout conformation of the RET kinase domain. These results strengthen the argument that Sorafenib may be effective in the treatment of MEN2 patients. In addition, because inhibition of RET is not impaired by mutation of the Val804 gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance.",
author = "Iv{\'a}n Plaza-Menacho and Luca Mologni and Elisa Sala and Carlo Gambacorti-Passerini and Magee, {Anthony I.} and Links, {Thera P.} and Hofstra, {Robert M W} and David Barford and Isacke, {Clare M.}",
year = "2007",
month = "10",
day = "5",
doi = "10.1074/jbc.M703461200",
language = "English",
volume = "282",
pages = "29230--29240",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "40",

}

TY - JOUR

T1 - Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting

AU - Plaza-Menacho, Iván

AU - Mologni, Luca

AU - Sala, Elisa

AU - Gambacorti-Passerini, Carlo

AU - Magee, Anthony I.

AU - Links, Thera P.

AU - Hofstra, Robert M W

AU - Barford, David

AU - Isacke, Clare M.

PY - 2007/10/5

Y1 - 2007/10/5

N2 - Germ line missense mutations in the RET (rearranged during transfection) oncogene are the cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only treatment available for MEN2 patients. In this study, the ability of Sorafenib (BAY 43-9006) to act as a RET inhibitor was investigated. Sorafenib inhibited the activity of purified recombinant kinase domain of wild type RET and RETV804M with IC50 values of 5.9 and 7.9 nM, respectively. Interestingly, these values were 6-7-fold lower than the IC50 for the inhibition of B-RAFV600E. In cell-based assays, Sorafenib inhibited the kinase activity and signaling of wild type and oncogenic RET in MEN2 tumor and established cell lines at a concentration between 15 and 150 nM. In contrast, inhibition of oncogenic B-RAF- or epidermal growth factor-induced ERK1/2 phosphorylation required micromolar concentrations of Sorafenib demonstrating the high specificity of this drug in targeting RET. Moreover, prolonged exposure to Sorafenib resulted in inhibition of cell proliferation and RET protein degradation. Using lysosomal and proteasomal inhibitors, we demonstrate that Sorafenib induces RET lysosomal degradation independent of proteasomal targeting. Furthermore, we provide a structural model of the Sorafenib·RET complex in which Sorafenib binds to and induces the DFGout conformation of the RET kinase domain. These results strengthen the argument that Sorafenib may be effective in the treatment of MEN2 patients. In addition, because inhibition of RET is not impaired by mutation of the Val804 gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance.

AB - Germ line missense mutations in the RET (rearranged during transfection) oncogene are the cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only treatment available for MEN2 patients. In this study, the ability of Sorafenib (BAY 43-9006) to act as a RET inhibitor was investigated. Sorafenib inhibited the activity of purified recombinant kinase domain of wild type RET and RETV804M with IC50 values of 5.9 and 7.9 nM, respectively. Interestingly, these values were 6-7-fold lower than the IC50 for the inhibition of B-RAFV600E. In cell-based assays, Sorafenib inhibited the kinase activity and signaling of wild type and oncogenic RET in MEN2 tumor and established cell lines at a concentration between 15 and 150 nM. In contrast, inhibition of oncogenic B-RAF- or epidermal growth factor-induced ERK1/2 phosphorylation required micromolar concentrations of Sorafenib demonstrating the high specificity of this drug in targeting RET. Moreover, prolonged exposure to Sorafenib resulted in inhibition of cell proliferation and RET protein degradation. Using lysosomal and proteasomal inhibitors, we demonstrate that Sorafenib induces RET lysosomal degradation independent of proteasomal targeting. Furthermore, we provide a structural model of the Sorafenib·RET complex in which Sorafenib binds to and induces the DFGout conformation of the RET kinase domain. These results strengthen the argument that Sorafenib may be effective in the treatment of MEN2 patients. In addition, because inhibition of RET is not impaired by mutation of the Val804 gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance.

UR - http://www.scopus.com/inward/record.url?scp=35748958721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748958721&partnerID=8YFLogxK

U2 - 10.1074/jbc.M703461200

DO - 10.1074/jbc.M703461200

M3 - Article

VL - 282

SP - 29230

EP - 29240

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 40

ER -